Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo

Ana C. DeCarvalho, Kevin Nelson, Nancy Lemke, Norman L. Lehman, Ali Syed Arbab, Steven Kalkanis, Tom Mikkelsen

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Cancer stem cells (CSCs) are characterized by their self-renewing potential and by their ability to differentiate and phenocopy the original tumor in orthotopic xenografts. Long-term propagation of glioblastoma (GBM) cells in serum-containing medium results in loss of the CSCs and outgrowth of cells genetically and biologically divergent from the parental tumors. In contrast, the use of a neurosphere assay, a serum-free culture for selection, and propagation of central nervous system-derived stem cells allows the selection of a subpopulation containing CSCs. Gliosarcoma (GS), a morphological variant comprising approximately 2% of GBMs, present a biphasic growth pattern, composed of glial and metaplastic mesenchymal components. To assess whether the neurosphere assay would allow the amplification of a subpopulation of cells with "gliosarcoma stem cell" properties, capable of propagating both components of this malignancy, we have generated neurospheres and serum cultures from primary GS and GBM surgical specimens. Neurosphere cultures from GBM and GS samples expressed neural stem cell markers Sox2, Musashi1, and Nestin. In contrast to the GBM neurosphere lines, the GS neurospheres were negative for the stem cell marker CD133. All neurosphere lines generated high-grade invasive orthotopic tumor xenografts, with histological features strikingly similar to the parental tumors, demonstrating that these cultures indeed are enriched in CSCs. Remarkably, low-passage GS serum cultures retained the expression of stem cell markers, the ability to form neurospheres, and tumorigenicity. The GS experimental tumors phenocopied the parental tumor, exhibiting biphasic glial and mesenchymal components, constituting a clinically relevant model to investigate mesenchymal differentiation in GBMs.

Original languageEnglish (US)
Pages (from-to)181-190
Number of pages10
JournalStem Cells
Volume28
Issue number2
DOIs
StatePublished - Feb 1 2010
Externally publishedYes

Fingerprint

Gliosarcoma
Neuroglia
Stem Cells
Neoplastic Stem Cells
Glioblastoma
Neoplasms
Serum
Heterografts
Nestin
Neural Stem Cells
Central Nervous System

Keywords

  • Cancer stem cells
  • Glioblastoma
  • Gliosarcoma
  • Mesenchymal differentiation
  • Neurospheres

ASJC Scopus subject areas

  • Molecular Medicine
  • Developmental Biology
  • Cell Biology

Cite this

DeCarvalho, A. C., Nelson, K., Lemke, N., Lehman, N. L., Arbab, A. S., Kalkanis, S., & Mikkelsen, T. (2010). Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells, 28(2), 181-190. https://doi.org/10.1002/stem.264

Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. / DeCarvalho, Ana C.; Nelson, Kevin; Lemke, Nancy; Lehman, Norman L.; Arbab, Ali Syed; Kalkanis, Steven; Mikkelsen, Tom.

In: Stem Cells, Vol. 28, No. 2, 01.02.2010, p. 181-190.

Research output: Contribution to journalArticle

DeCarvalho, AC, Nelson, K, Lemke, N, Lehman, NL, Arbab, AS, Kalkanis, S & Mikkelsen, T 2010, 'Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo', Stem Cells, vol. 28, no. 2, pp. 181-190. https://doi.org/10.1002/stem.264
DeCarvalho AC, Nelson K, Lemke N, Lehman NL, Arbab AS, Kalkanis S et al. Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. Stem Cells. 2010 Feb 1;28(2):181-190. https://doi.org/10.1002/stem.264
DeCarvalho, Ana C. ; Nelson, Kevin ; Lemke, Nancy ; Lehman, Norman L. ; Arbab, Ali Syed ; Kalkanis, Steven ; Mikkelsen, Tom. / Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo. In: Stem Cells. 2010 ; Vol. 28, No. 2. pp. 181-190.
@article{793d2c7e68304b9c803a409abc236d25,
title = "Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo",
abstract = "Cancer stem cells (CSCs) are characterized by their self-renewing potential and by their ability to differentiate and phenocopy the original tumor in orthotopic xenografts. Long-term propagation of glioblastoma (GBM) cells in serum-containing medium results in loss of the CSCs and outgrowth of cells genetically and biologically divergent from the parental tumors. In contrast, the use of a neurosphere assay, a serum-free culture for selection, and propagation of central nervous system-derived stem cells allows the selection of a subpopulation containing CSCs. Gliosarcoma (GS), a morphological variant comprising approximately 2{\%} of GBMs, present a biphasic growth pattern, composed of glial and metaplastic mesenchymal components. To assess whether the neurosphere assay would allow the amplification of a subpopulation of cells with {"}gliosarcoma stem cell{"} properties, capable of propagating both components of this malignancy, we have generated neurospheres and serum cultures from primary GS and GBM surgical specimens. Neurosphere cultures from GBM and GS samples expressed neural stem cell markers Sox2, Musashi1, and Nestin. In contrast to the GBM neurosphere lines, the GS neurospheres were negative for the stem cell marker CD133. All neurosphere lines generated high-grade invasive orthotopic tumor xenografts, with histological features strikingly similar to the parental tumors, demonstrating that these cultures indeed are enriched in CSCs. Remarkably, low-passage GS serum cultures retained the expression of stem cell markers, the ability to form neurospheres, and tumorigenicity. The GS experimental tumors phenocopied the parental tumor, exhibiting biphasic glial and mesenchymal components, constituting a clinically relevant model to investigate mesenchymal differentiation in GBMs.",
keywords = "Cancer stem cells, Glioblastoma, Gliosarcoma, Mesenchymal differentiation, Neurospheres",
author = "DeCarvalho, {Ana C.} and Kevin Nelson and Nancy Lemke and Lehman, {Norman L.} and Arbab, {Ali Syed} and Steven Kalkanis and Tom Mikkelsen",
year = "2010",
month = "2",
day = "1",
doi = "10.1002/stem.264",
language = "English (US)",
volume = "28",
pages = "181--190",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "2",

}

TY - JOUR

T1 - Gliosarcoma stem cells undergo glial and mesenchymal differentiation in vivo

AU - DeCarvalho, Ana C.

AU - Nelson, Kevin

AU - Lemke, Nancy

AU - Lehman, Norman L.

AU - Arbab, Ali Syed

AU - Kalkanis, Steven

AU - Mikkelsen, Tom

PY - 2010/2/1

Y1 - 2010/2/1

N2 - Cancer stem cells (CSCs) are characterized by their self-renewing potential and by their ability to differentiate and phenocopy the original tumor in orthotopic xenografts. Long-term propagation of glioblastoma (GBM) cells in serum-containing medium results in loss of the CSCs and outgrowth of cells genetically and biologically divergent from the parental tumors. In contrast, the use of a neurosphere assay, a serum-free culture for selection, and propagation of central nervous system-derived stem cells allows the selection of a subpopulation containing CSCs. Gliosarcoma (GS), a morphological variant comprising approximately 2% of GBMs, present a biphasic growth pattern, composed of glial and metaplastic mesenchymal components. To assess whether the neurosphere assay would allow the amplification of a subpopulation of cells with "gliosarcoma stem cell" properties, capable of propagating both components of this malignancy, we have generated neurospheres and serum cultures from primary GS and GBM surgical specimens. Neurosphere cultures from GBM and GS samples expressed neural stem cell markers Sox2, Musashi1, and Nestin. In contrast to the GBM neurosphere lines, the GS neurospheres were negative for the stem cell marker CD133. All neurosphere lines generated high-grade invasive orthotopic tumor xenografts, with histological features strikingly similar to the parental tumors, demonstrating that these cultures indeed are enriched in CSCs. Remarkably, low-passage GS serum cultures retained the expression of stem cell markers, the ability to form neurospheres, and tumorigenicity. The GS experimental tumors phenocopied the parental tumor, exhibiting biphasic glial and mesenchymal components, constituting a clinically relevant model to investigate mesenchymal differentiation in GBMs.

AB - Cancer stem cells (CSCs) are characterized by their self-renewing potential and by their ability to differentiate and phenocopy the original tumor in orthotopic xenografts. Long-term propagation of glioblastoma (GBM) cells in serum-containing medium results in loss of the CSCs and outgrowth of cells genetically and biologically divergent from the parental tumors. In contrast, the use of a neurosphere assay, a serum-free culture for selection, and propagation of central nervous system-derived stem cells allows the selection of a subpopulation containing CSCs. Gliosarcoma (GS), a morphological variant comprising approximately 2% of GBMs, present a biphasic growth pattern, composed of glial and metaplastic mesenchymal components. To assess whether the neurosphere assay would allow the amplification of a subpopulation of cells with "gliosarcoma stem cell" properties, capable of propagating both components of this malignancy, we have generated neurospheres and serum cultures from primary GS and GBM surgical specimens. Neurosphere cultures from GBM and GS samples expressed neural stem cell markers Sox2, Musashi1, and Nestin. In contrast to the GBM neurosphere lines, the GS neurospheres were negative for the stem cell marker CD133. All neurosphere lines generated high-grade invasive orthotopic tumor xenografts, with histological features strikingly similar to the parental tumors, demonstrating that these cultures indeed are enriched in CSCs. Remarkably, low-passage GS serum cultures retained the expression of stem cell markers, the ability to form neurospheres, and tumorigenicity. The GS experimental tumors phenocopied the parental tumor, exhibiting biphasic glial and mesenchymal components, constituting a clinically relevant model to investigate mesenchymal differentiation in GBMs.

KW - Cancer stem cells

KW - Glioblastoma

KW - Gliosarcoma

KW - Mesenchymal differentiation

KW - Neurospheres

UR - http://www.scopus.com/inward/record.url?scp=77149154049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77149154049&partnerID=8YFLogxK

U2 - 10.1002/stem.264

DO - 10.1002/stem.264

M3 - Article

C2 - 19937755

AN - SCOPUS:77149154049

VL - 28

SP - 181

EP - 190

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 2

ER -